CR20220062A - Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina - Google Patents

Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina

Info

Publication number
CR20220062A
CR20220062A CR20220062A CR20220062A CR20220062A CR 20220062 A CR20220062 A CR 20220062A CR 20220062 A CR20220062 A CR 20220062A CR 20220062 A CR20220062 A CR 20220062A CR 20220062 A CR20220062 A CR 20220062A
Authority
CR
Costa Rica
Prior art keywords
pyrazolo
pyrazine
phosphatase inhibitors
shp2 phosphatase
compounds
Prior art date
Application number
CR20220062A
Other languages
English (en)
Inventor
Steven Howard
Tadashi Shimamura
John Walter Liebeschuetz
Original Assignee
Taiho Pharmaceutical Co Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd, Otsuka Pharma Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CR20220062A publication Critical patent/CR20220062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invencion proporciona nuevos derivados de pirazina de formula (I): (I) <img src="data:image/png;base64,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 (***)
CR20220062A 2019-08-20 2020-08-20 Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina CR20220062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1911928.8A GB201911928D0 (en) 2019-08-20 2019-08-20 Pharmaceutical compounds
PCT/IB2020/057815 WO2021033153A1 (en) 2019-08-20 2020-08-20 Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors

Publications (1)

Publication Number Publication Date
CR20220062A true CR20220062A (es) 2022-04-20

Family

ID=68099585

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220062A CR20220062A (es) 2019-08-20 2020-08-20 Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina

Country Status (18)

Country Link
US (1) US20230049719A1 (es)
EP (1) EP4017855A1 (es)
JP (1) JP2022546213A (es)
KR (1) KR20220049518A (es)
CN (1) CN114206885A (es)
AU (1) AU2020333251A1 (es)
BR (1) BR112022003184A2 (es)
CA (1) CA3148312A1 (es)
CL (1) CL2022000271A1 (es)
CO (1) CO2022001357A2 (es)
CR (1) CR20220062A (es)
EC (1) ECSP22011086A (es)
GB (1) GB201911928D0 (es)
IL (1) IL289462A (es)
MX (1) MX2022001908A (es)
PE (1) PE20220931A1 (es)
TW (1) TW202124383A (es)
WO (1) WO2021033153A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902415A (zh) 2018-03-02 2020-11-06 大冢制药株式会社 药学化合物
MX2021000795A (es) 2018-07-24 2021-04-12 Taiho Pharmaceutical Co Ltd Compuestos heterociclicos para inhibir la actividad de shp2.
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
WO2022014640A1 (ja) 2020-07-15 2022-01-20 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
KR20230081726A (ko) 2020-09-03 2023-06-07 레볼루션 메디슨즈, 인크. Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
JP2023541916A (ja) 2020-09-15 2023-10-04 レボリューション メディシンズ インコーポレイテッド がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
EP4334321A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
CN116323616A (zh) * 2021-07-07 2023-06-23 浙江同源康医药股份有限公司 用作shp2抑制剂的化合物及其应用
EP4395769A1 (en) 2021-09-01 2024-07-10 Novartis AG Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
CN118019743A (zh) * 2021-09-28 2024-05-10 甘李药业股份有限公司 可用作shp2抑制剂的化合物及其制备方法和用途
WO2023051717A1 (zh) * 2021-09-29 2023-04-06 微境生物医药科技(上海)有限公司 作为shp2抑制剂的稠环化合物
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
JP6878316B2 (ja) 2015-06-19 2021-05-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
JP7044375B2 (ja) * 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｐｔｐｎ１１の複素環式阻害剤
CN112250670B (zh) * 2016-06-07 2021-06-08 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US11529347B2 (en) * 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
EP3768680A1 (en) 2018-03-21 2021-01-27 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
EP3787627A4 (en) 2018-05-02 2021-12-01 Navire Pharma, Inc. SUBSTITUTED HETEROCYCLIC INHIBITORS FOR PTPN11

Also Published As

Publication number Publication date
ECSP22011086A (es) 2022-03-31
CA3148312A1 (en) 2021-02-25
IL289462A (en) 2022-02-01
WO2021033153A1 (en) 2021-02-25
US20230049719A1 (en) 2023-02-16
CL2022000271A1 (es) 2022-10-28
MX2022001908A (es) 2022-04-18
CO2022001357A2 (es) 2022-03-18
GB201911928D0 (en) 2019-10-02
AU2020333251A1 (en) 2022-02-17
CN114206885A (zh) 2022-03-18
BR112022003184A2 (pt) 2022-05-17
EP4017855A1 (en) 2022-06-29
JP2022546213A (ja) 2022-11-04
KR20220049518A (ko) 2022-04-21
PE20220931A1 (es) 2022-05-31
TW202124383A (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
NZ766835A (en) Pharmaceutical compounds
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
GEP20227433B (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
MX2021007247A (es) Derivados de rapamicina.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof